about
Hepatotoxicity in a 52-week randomized trial of short-term versus long-term treatment with buprenorphine/naloxone in HIV-negative injection opioid users in China and ThailandA review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world.Effects of buprenorphine and hepatitis C on liver enzymes in adolescents and young adults.Effect of hepatitis C virus status on liver enzymes in opioid-dependent pregnant women maintained on opioid-agonist medication.New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone.Short-term safety of buprenorphine/naloxone in HIV-seronegative opioid-dependent Chinese and Thai drug injectors enrolled in HIV Prevention Trials Network 058.Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: a randomized trialCan the chronic administration of the combination of buprenorphine and naloxone block dopaminergic activity causing anti-reward and relapse potential?Withdrawal from Buprenorphine/Naloxone and Maintenance with a Natural Dopaminergic Agonist: A Cautionary Note.Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone.Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection.Liver enzyme levels in adolescent patients treated with buprenorphine and additional psychotropic agents.Acute hepatitis and renal failure related to intranasal buprenorphine misuse: case report and analysis of cases reported to the French network for drug monitoring.Effects of buprenorphine on balance of oxidant/antioxidant system in the different ages of male rat liver.Fulminant hepatic failure after intravenous injection of sublingual buprenorphine in a patient with hepatitis C.Buprenorphine in the treatment of opiate dependence.Hepatitis after intravenous injection of sublingual buprenorphine in acute hepatitis C carriers: report of two cases of disappearance of viral replication after acute hepatitis.Buprenorphine-naloxone treatment in opioid dependence and risk of liver enzyme elevation: results from a 12-month observational study.Analgesics in patients with hepatic impairment: pharmacology and clinical implications.
P2860
Q34022193-C76798F6-C2F8-4445-A34C-52343BA14DBEQ34253036-65A3F3A5-D114-4475-B042-3576C82B5031Q34407721-31B3BA00-6BF0-4044-ACA9-8750AF79E25EQ34721038-7EDE4D19-EF2B-4038-8812-B06E752BFD5CQ34952233-26496C11-917C-4253-A7B4-243967C47605Q35608547-4354B130-F1B8-412E-99EA-79F0BB21C1F2Q36527454-838C5BD0-9796-4864-948F-39F83B4356B3Q36928874-B13C1AB6-C0DE-48AA-955F-68D65CE9E6A3Q37329865-10FD999D-8D71-4A04-8C5E-F9DF13F4569FQ37393366-1547CFAA-4865-444D-85E6-01673F1DCBA1Q38901411-DE72CD16-1064-4BE9-A680-AE79186AD845Q41711349-4CE731C9-21F4-453A-AF3B-CBA23FD514B3Q42254138-23224D46-BE10-4279-9220-BEE665B51FC0Q42702559-E06361A3-1D70-41FF-A4CC-EFAC0ABBC2AAQ42911746-77B6FFD0-1833-4DCC-8581-E69F9C92C13DQ42962930-9EA9107A-5189-4ABB-A6CF-DFEFCBAF4ACEQ42987036-7E7D7126-B52A-4AFF-8ED4-336E31D8FF97Q44347273-3719E392-745F-4BA1-93A7-DFD51E8729FEQ53689504-C967AE2C-AEEF-476C-BF0B-B52519DA6F77
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Acute hepatitis due to buprenorphine administration.
@en
type
label
Acute hepatitis due to buprenorphine administration.
@en
prefLabel
Acute hepatitis due to buprenorphine administration.
@en
P2093
P1476
Acute hepatitis due to buprenorphine administration.
@en
P2093
Catherine Noblet
Christian Thuillez
Eric Lerebours
Ghassan Riachi
Jean-Luc Tranvouez
Nathalie Guillement
Odile Goria
Philippe Ducrotte
Sophie Hervé
Stephana Tanasescu
P304
P356
10.1097/00042737-200410000-00013
P577
2004-10-01T00:00:00Z